Jerome solassol

List of Publications by Year
in descending order

87	3,155	159525 30	168321 53
papers	citations	h-index	g-index

99	99	99	5568
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Establishment and Characterization of a Cell Line from Human Circulating Colon Cancer Cells. Cancer Research, 2015, 75, 892-901.	0.4	321
2	Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Annals of Oncology, 2014, 25, 126-131.	0.6	270
3	Cationic phosphorus-containing dendrimers reduce prion replication both in cell culture and in mice infected with scrapie. Journal of General Virology, 2004, 85, 1791-1799.	1.3	172
4	Proteomics-Based Identification of HSP60 as a Tumor-Associated Antigen in Early Stage Breast Cancer and Ductal Carcinoma in situ. Journal of Proteome Research, 2008, 7, 3830-3837.	1.8	115
5	Anti-PrP antibodies block PrPScreplication in prion-infected cell cultures by accelerating PrPCdegradation. Journal of Neurochemistry, 2004, 89, 454-463.	2.1	111
6	Autoantibody signatures: progress and perspectives for early cancer detection. Journal of Cellular and Molecular Medicine, 2011, 15, 2013-2024.	1.6	100
7	Identification of a New Panel of Serum Autoantibodies Associated with the Presence of In situ Carcinoma of the Breast in Younger Women. Clinical Cancer Research, 2009, 15, 4733-4741.	3.2	99
8	Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches. Scientific Reports, 2017, 7, 12510.	1.6	81
9	Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. European Journal of Cancer, 2021, 146, 30-47.	1.3	81
10	Prion propagation in cultured cells. British Medical Bulletin, 2003, 66, 87-97.	2.7	77
11	Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management. International Journal of Molecular Sciences, 2017, 18, 264.	1.8	76
12	Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Nonâ€“Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Projectâ€”Part 2). Journal of Thoracic Oncology, 2012, 7, 1490-1502.	0.5	69
13	HDL Proteome in Hemodialysis Patients: A Quantitative Nanoflow Liquid Chromatography-Tandem Mass Spectrometry Approach. PLoS ONE, 2012, 7, e34107.	1.1	67
14	KRAS Mutation Detection in Paired Frozen and Formalin-Fixed Paraffin-Embedded (FFPE) Colorectal Cancer Tissues. International Journal of Molecular Sciences, 2011, 12, 3191-3204.	1.8	52
15	<scp>VIM</scp>â€1 carbapenemaseâ€producing Escherichia coli in gulls from southern France. Ecology and Evolution, 2017, 7, 1224-1232.	0.8	51
16	FKBP family proteins as promising new biomarkers for cancer. Current Opinion in Pharmacology, 2011, 11, 320-325.	1.7	50
17	Liquid Chromatography-Tandem and MALDI Imaging Mass Spectrometry Analyses of RCL2/CS100-Fixed, Paraffin-Embedded Tissues: Proteomics Evaluation of an Alternate Fixative for Biomarker Discovery. Journal of Proteome Research, 2009, 8, 5619-5628.	1.8	49
18	Proteomic approaches to identify biomarkers predictive of radiotherapy outcomes. Expert Review of Proteomics, 2013, 10, 33-42.	1.3	48

#	Article	IF	Citations
19	Comprehensive proteomic analysis of the human milk proteome: Contribution of protein fractionation. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 876, 252-256.	1.2	46
20	Proteomic detection of prostate-specific antigen using a serum fractionation procedure: potential implication for new low-abundance cancer biomarkers detection. Analytical Biochemistry, 2005, 338, 26-31.	1.1	45
21	Clinical proteomics and mass spectrometry profiling for cancer detection. Expert Review of Proteomics, 2006, 3, 311-320.	1.3	43
22	FKBP4 connects mTORC2 and PI3K to activate the PDK1/Akt-dependent cell proliferation signaling in breast cancer. Theranostics, 2019, 9, 7003-7015.	4.6	43
23	Improvement of protein immobilization for the elaboration of tumor-associated antigen microarrays: Application to the sensitive and specific detection of tumor markers from breast cancer sera. Biosensors and Bioelectronics, 2013, 40, 385-392.	5.3	41
24	Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative earlyâ€stage breast cancers. International Journal of Cancer, 2013, 132, 1105-1113.	2.3	41
25	Proteomic profile determination of autosomal aneuploidies by mass spectrometry on amniotic fluids. Proteome Science, 2008, 6, 1.	0.7	39
26	Use of Autoantibodies to Detect the Onset of Breast Cancer. Journal of Immunology Research, 2014, 2014, 1-8.	0.9	38
27	Serum Autoantibody Signature of Ductal Carcinoma In Situ Progression to Invasive Breast Cancer. Clinical Cancer Research, 2012, 18, 1992-2000.	3.2	36
28	Multi-Center Evaluation of the Fully Automated PCR-Based Idyllaâ„¢ KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal Cancer. PLoS ONE, 2016, 11, e0163444.	1.1	35
29	EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma. International Journal of Molecular Sciences, 2013, 14, 5170-5181.	1.8	32
30	A Multicenter Blinded Study Evaluating EGFR and KRAS Mutation Testing Methods in the Clinical Nonâ€“Small Cell Lung Cancer Settingâ€”IFCT/ERMETIC2 Project Part 1. Journal of Molecular Diagnostics, 2014, 16, 45-55.	1.2	31
31	Ultra-sensitive EGFRT790M Detection as an Independent Prognostic Marker for Lung Cancer Patients Harboring EGFRdel19 Mutations and Treated with First-generation TKIs. Clinical Cancer Research, 2019, 25, 4280-4289.	3.2	31
32	Clinical Relevance of Autoantibody Detection in Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 955-962.	0.5	30
33	Cell Culture Models of Transmissible Spongiform Encephalopathies. Biochemical and Biophysical Research Communications, 2001, 289, 311-316.	1.0	28
34	Humoral response to cancer as a tool for biomarker discovery. Journal of Proteomics, 2009, 72, 982-988.	1.2	28
35	Identifying autoantibody signatures in cancer: a promising challenge. Expert Review of Proteomics, 2009, 6, 377-386.	1.3	28
36	Serum Proteomic Profiling of Lung Cancer in High-Risk Groups and Determination of Clinical Outcomes. Journal of Thoracic Oncology, 2008, 3, 840-850.	0.5	26

#	Article	IF	Citations
37	Serum protein signature may improve detection of ductal carcinoma in situ of the breast. Oncogene, 2010, 29, 550-560.	2.6	24
38	Pemphigus vulgaris antigen mRNA quantification for the staging of sentinel lymph nodes in head and neck cancer. British Journal of Cancer, 2010, 102, 181-187.	2.9	24
39	Detection of BRAF V600 Mutations in Melanoma: Evaluation of Concordance between the CobasÂ® 4800 BRAF V600 Mutation Test and the Methods Used in French National Cancer Institute (INCa) Platforms in a Real-Life Setting. PLoS ONE, 2015, 10, e0120232.	1.1	24
40	Specific increase of human kallikrein 4 mRNA and protein levels in breast cancer stromal cells. Biochemical and Biophysical Research Communications, 2008, 375, 107-112.	1.0	23
41	High Prevalence of SXT/R391-Related Integrative and Conjugative Elements Carrying bla _{CMY-2} in Proteus mirabilis Isolates from Gulls in the South of France. Antimicrobial Agents and Chemotherapy, 2016, 60, 1148-1152.	1.4	23
42	A Novel Copperâ€“Hydrogen Peroxide Formulation for Prion Decontamination. Journal of Infectious Diseases, 2006, 194, 865-869.	1.9	22
43	An integrated cell line-based discovery strategy identified follistatin and kallikrein 6 as serum biomarker candidates of breast carcinoma. Journal of Proteomics, 2016, 142, 114-121.	1.2	22
44	A Multiparametric Serum Marker Panel as a Complementary Test to Mammography for the Diagnosis of Node-Negative Early-Stage Breast Cancer and DCIS in Young Women. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1834-1842.	1.1	21
45	First Description of IncX3 Plasmids Carrying bla _{OXA-181} in Escherichia coli Clinical Isolates in Burkina Faso. Antimicrobial Agents and Chemotherapy, 2016, 60, 3240-3242.	1.4	21
46	Comparative evaluation of the new FDA approved THxIDâ„¢-BRAF test with high resolution melting and sanger sequencing. BMC Cancer, 2014, 14, 519.	1.1	20
47	Late side-effects after curative intent radiotherapy: Identification of hypersensitive patients for personalized strategy. Critical Reviews in Oncology/Hematology, 2015, 93, 312-319.	2.0	20
48	Detection of prion after decontamination procedures: comparative study of standard Western blot, filter retention and scrapie-cell assay. Journal of Hospital Infection, 2004, 57, 156-161.	1.4	17
49	Highly sensitive detection of melanoma based on serum proteomic profiling. Journal of Cancer Research and Clinical Oncology, 2009, 135, 1257-1264.	1.2	17
50	Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer. Cancers, 2020, 12, 2184.	1.7	17
51	Cutaneous Epithelial Tumors Induced by Vemurafenib Involve the MAPK and Pi3KCA Pathways but Not HPV nor HPyV Viral Infection. PLoS ONE, 2014, 9, e110478.	1.1	16
52	Rapid detection of common autosomal aneuploidies by quantitative fluorescent PCR on uncultured amniocytes. European Journal of Human Genetics, 2002, 10, 462-466.	1.4	15
53	Evaluation of the SLOMYCO SensititreÂ® panel for testing the antimicrobial susceptibility of Mycobacterium marinum isolates. Annals of Clinical Microbiology and Antimicrobials, 2016, 15, 30.	1.7	15
54	Serum Proteomic Profiling Reveals Potential Biomarkers for Cutaneous Malignant Melanoma. International Journal of Biological Markers, 2011, 26, 82-87.	0.7	14

#	Article	IF	Citations
55	High Nasal Carriage Rate of Staphylococcus aureus Containing Panton-Valentine leukocidin- and EDIN-Encoding Genes in Community and Hospital Settings in Burkina Faso. Frontiers in Microbiology, 2016, 7, 1406.	1.5	14
56	High-throughput detection of clinically targetable alterations using next-generation sequencing. Oncotarget, 2017, 8, 40345-40358.	0.8	14
57	The contribution of proteomics to the identification of biomarkers for cutaneous malignant melanoma. Clinical Biochemistry, 2013, 46, 518-523.	0.8	13
58	Anti-heat shock protein autoantibody profiling in breast cancer using customized protein microarray. Analytical and Bioanalytical Chemistry, 2016, 408, 1497-1506.	1.9	12
59	Improving Mutation Screening in Patients with Colorectal Cancer Predisposition Using Next-Generation Sequencing. Journal of Molecular Diagnostics, 2017, 19, 589-601.	1.2	11
60	Reconstruction and signal propagation analysis of the Syk signaling network in breast cancer cells. PLoS Computational Biology, 2017, 13, e1005432.	1.5	11
61	MIAmS: microsatellite instability detection on NGS amplicons data. Bioinformatics, 2019, , .	1.8	10
62	Thiopurine Drugs in the Treatment of Ulcerative Colitis: Identification of a Novel Deleterious Mutation in TPMT. Genes, 2020, 11, 1212.	1.0	10
63	Epstein-Barr Virus DNA Quantitation Assessed by a Real-Time Polymerase Chain Reaction in a Case of Burkitt's Lymphoma. Leukemia and Lymphoma, 2001, 41, 669-673.	0.6	9
64	Comparison of five cell-free DNA isolation methods to detect the EGFR T790M mutation in plasma samples of patients with lung cancer. Clinical Chemistry and Laboratory Medicine, 2018, 56, e243-e246.	1.4	9
65	Benchmarking of Amplicon-Based Next-Generation Sequencing Panels Combined with Bioinformatics Solutions for Germline BRCA1 and BRCA2 Alteration Detection. Journal of Molecular Diagnostics, 2018, 20, 754-764.	1.2	9
66	Detection of trisomy 21 by quantitative fluorescent-polymerase chain reaction in uncultured amniocytes. Prenatal Diagnosis, 2003, 23, 287-291.	1.1	8
67	Elevated Concentrations of Milk Î²2-Microglobulin Are Associated with Increased Risk of Breastfeeding Transmission of HIV-1 (Vertical Transmission Study). Journal of Proteome Research, 2013, 12, 5616-5625.	1.8	8
68	Quantitative proteomic analysis reveals AK2 as potential biomarker for late normal tissue radiotoxicity. Radiation Oncology, 2019, 14, 142.	1.2	8
69	Alu element insertion in the MLH1 exon 6 coding sequence as a mutation predisposing to Lynch syndrome. Human Mutation, 2019, 40, 716-720.	1.1	8
70	TERT Promoter Mutation as an Independent Prognostic Marker for Poor Prognosis MAPK Inhibitors-Treated Melanoma. Cancers, 2020, 12, 2224.	1.7	8
71	Comparative Methods to Improve the Detection of BRAF V600 Mutations in Highly Pigmented Melanoma Specimens. PLoS ONE, 2016, 11, e0158698.	1.1	8
72	Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations. Cancers, 2022, 14, 1132.	1.7	8

#	Article	IF	Citations
73	Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives. Cancers, 2022, 14, 1098.	1.7	8
74	Investigation of pre-XDR Beijing Mycobacterium tuberculosis transmission to a healthcare worker in France, 2016. Journal of Hospital Infection, 2017, 97, 414-417.	1.4	7
75	Further delineation of the <scp>NTHL1</scp> associated syndrome: A report from the French Oncogenetic Consortium. Clinical Genetics, 2021, 99, 662-672.	1.0	7
76	Comparison of Supervised Classification Methods for Protein Profiling in Cancer Diagnosis. Cancer Informatics, 2007, 3, 117693510700300.	0.9	6
77	Proximal Protein Interaction Landscape of RAS Paralogs. Cancers, 2020, 12, 3326.	1.7	6
78	CD44v6 Defines a New Population of Circulating Tumor Cells Not Expressing EpCAM. Cancers, 2021, 13, 4966.	1.7	6
79	Comparison of supervised classification methods for protein profiling in cancer diagnosis. Cancer Informatics, 2007, 3, 295-305.	0.9	5
80	EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcome. Translational Lung Cancer Research, 2021, 10, 4084-4094.	1.3	5
81	Persistence of bla CMY-2 -producing Proteus mirabilis in two gull colonies at a 1-year interval in Southern France. Journal of Global Antimicrobial Resistance, 2017, 9, 138-140.	0.9	3
82	Identification of serum melanoma progression biomarkers through proteomic-based approaches. Expert Review of Proteomics, 2009, 6, 341-343.	1.3	2
83	Determination of the Optimal Bacterial DNA Extraction Method to Explore the Urinary Microbiota. International Journal of Molecular Sciences, 2022, 23, 1336.	1.8	2
84	Morphological and molecular analysis of lung cancer biopsies fixed in RCL2. Histopathology, 2013, 63, 137-139.	1.6	1
85	No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in BRCA1 or BRCA2 Mutation Families. Genes, 2021, 12, 1100.	1.0	1
86	R147: Biologie molÃ©culaire des tumeurs : optimisation de la prise en charge par lâ€™Ã©laboration dâ€™arbres dÃ©cisionnels mÃ©thodologiques. Bulletin Du Cancer, 2010, 97, S74.	0.6	0
87	Cell Culture Models of TSEs. , 2004, , 72-81.		0